Knee Arthritis
Conditions
Keywords
knee arthritis, morphine, local injection, pain
Brief summary
To investigate pain and inflammatory parameters (cytokines, immune cells) in knee joint tissue of chronic arthritis patients following intraarticular (i.a.) injections of morphine, a standard steroid or placebo. The primary hypothesis is that i.a. morphine results in significantly lower pain scores and supplemental analgesic consumption than placebo during the first week after injection, an efficacy comparable to standard i.a. steroid (triamcinolone) medication.
Detailed description
3 arm, double blind, placebo controlled, prospective, mo-nocenter study, which will be conducted in the Department of Rheumatology, Charité University Medicine Berlin, Cam-pus Benjamin Franklin in collaboration with several rheu-matology and orthopedic practices in the Berlin area. Ultra-sound guided synovial needle biopsy and interventions will only be performed at CBF. Eligible patients will be treated with either morphine 3 mg i.a., NaCl 0.9% i.a. or triamcinolone 40 mg i.a. at Baseline. The entire study period will be 2 weeks per patient. Assessment of the primary outcome parameter will be at week 1. The patients will be monitored closely throughout the entire study period with a total of 4 visits (screening, baseline, week 1, week 2). Safety data will be collected in the adverse events form, vital parameters, physical examination and laboratory tests dur-ing the whole study.
Interventions
DRUGMorphine Sulfate
active intervention
DRUGTriamcinolone
active control
DRUGplacebo
placebo control
Sponsors
DLR German Aerospace Center
Hildrun Haibel
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Clinically detectable and/or ultrasound-visible knee ef-fusion as part of spondyloarthritis (Assessments in SpondyloArthritis international Society, ASAS criteria), Rheumatoid Arthritis, RA (according to American Col-lege of Rheumatology, ACR criteria), undifferentiated mono- or oligoarthritis, Osteoarthritis of the knee, OA. 2. baseline pain score (on a 100 mm Visual Analogue Scale, VAS) \>40 mm; 3. male and female patients, age ≥18 - 80 years, 4. body weight 50 - 90 kg. 5. Able and willing to give a written informed consent and comply with the requirements of the study protocol. Only patients who give written informed consent will be in-cluded in the trial. 6. If female: either not of child-bearing potential (meno-pausal since 1 year or surgically sterile) or is willing and able to practice a reliable method of contraception throughout the study with a pearl index \<1. Reliable methods of contraception are: condoms plus other methods: implants, injecatbles, combined oral contracep-tives, intrauterine devices, initiated at least 90 days prior to screening. Further reliable methods are a vasecto-mised partner (at least 1 year prior to enrolment), sexual-ly abstinent, surgically sterilized (including hysterecto-my), postmenopausal defined as at least 1 year of spon-taneous amenorrhea (in questionable cases a blood sample with simultaneous levels of follicle stimulating hormone (FSH) above 40 U/l and estradiol below 30 nl/l is confirmatory). 7. If male: either not of child-bearing potential (surgically sterilized, e.g. vasectomy) or is willing and able to prac-tice a reliable method of contraception with a pearl index \<1 (see inclusion criterium 6) throughout the study.
Exclusion criteria
1. Severe cardiovascular, respiratory, metabolic, neurologi-cal, psychiatric disorders; current bacterial infection es-pecially of the knee 2. abuse of analgesics, benzodiazepines, alcohol; hard drugs 3. pregnancy, lactation 4. before biopsy thrombocyte count \< 100/nl, Quick \<50% 5. intake of anticoagulants, anti-aggregants as monothera-py such as ASS 100 will be allowed 6. participation in an investigational trial during the last 30 days or 5 HLT whichever is longer 7. treatment with intraarticular steroids during the past 4 weeks in the selected joint. 8. Patients with a history of a severe psychiatric illness, which might interfere with the patient's ability to under-stand the requirements of the study and assessment. 9. Patients who are institutionalised due to regulatory or juridical order. Patients who are an employee of the in-vestigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator. 10. Known hypersensitivity to any component of the study medication to morphine or triamcinolone, ileus, respira-tory depression, severe chronic obstructive airway dis-eases, acute abdomen, coagulopathy and/ or infections of the injection site, instability of the injected joint, psori-atic skin manifestation at the injection site, periarticular calcification, non-vascularized bone necrosis, tendon rupture, Charcot-joint.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction of pain intensity (on a 100mm VAS) at 8 a.m. on day 7 compared to baseline | 1 week | Reduction of pain intensity (on a 100mm VAS) at 8 a.m. on day 7 compared to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain intensity on McGill pain questionnaire (MPQ) at baseline, week 1 and 2 | 2 weeks | Pain intensity on McGill pain questionnaire (MPQ) at baseline, week 1 and 2 |
| daily activities at baseline, week 1 and 2 | 2 weeks | daily activities at baseline, week 1 and 2 |
| activity and mobility of the knee joint (Lysholm Gilquist-Score) at baseline, week 1 and 2 | 2 weeks | activity and mobility of the knee joint (Lysholm Gilquist-Score) at baseline, week 1 and 2 |
| Area under the VAS curve (AUC) of VAS pain during the first week until 8 p.m. on day 7 | 1 week | Area under the VAS curve (AUC) of VAS pain during the first week until 8 p.m. on day 7 |
| nflammatory parameters (cellular infiltrate, opioid receptors and peptides, IL-17, TNFα) in synovial biopsies and fluid (before i.a. medication at baseline and week 1), | 1 weeks | nflammatory parameters (cellular infiltrate, opioid receptors and peptides, IL-17, TNFα) in synovial biopsies and fluid (before and 7 days af-ter i.a. medication), |
| supplementary analgesic consumption continuously in the patients diary, recorded at week 1 and 2 | 2 weeks | supplementary analgesic consumption continuously in the patients diary, recorded at week 1 and 2 |
| Any systemic (e.g. nausea, sedation) and local side effects (infection, tissue injury) will be recorded continuously in the patients diary, recorded at week 1 and week 2. | Screening, Baseline, week 1, week 2 | Any systemic (e.g. nausea, sedation) and local side effects (infection, tissue injury) will be recorded continuously in the patients diary, recorded at week 1 and 2. |
| WOMAC scale (before i.a. injections at baseline, week 1 and 2) | 2 weeks | WOMAC scale (before i.a. injections and at the end of each week) |
Countries
Germany
Outcome results
None listed